PMC:7029759 / 11747-11947 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"277","span":{"begin":124,"end":174},"obj":"Disease"}],"attributes":[{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"MESH:D006526"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T211","span":{"begin":37,"end":42},"obj":"NCBITaxon:10239"},{"id":"T210","span":{"begin":71,"end":81},"obj":"CHEBI:37670;CHEBI:37670"},{"id":"T209","span":{"begin":118,"end":123},"obj":"SP_6;NCBITaxon:9606"},{"id":"T208","span":{"begin":141,"end":146},"obj":"NCBITaxon:10376"},{"id":"T207","span":{"begin":157,"end":166},"obj":"NCBITaxon:5690"},{"id":"T206","span":{"begin":167,"end":174},"obj":"NCBITaxon:10376"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T59","span":{"begin":148,"end":151},"obj":"Body_part"}],"attributes":[{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T30","span":{"begin":124,"end":140},"obj":"Disease"},{"id":"T31","span":{"begin":157,"end":168},"obj":"Disease"},{"id":"T32","span":{"begin":157,"end":166},"obj":"Disease"}],"attributes":[{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T101","span":{"begin":118,"end":123},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T102","span":{"begin":141,"end":146},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T103","span":{"begin":169,"end":174},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T34","span":{"begin":62,"end":81},"obj":"Chemical"},{"id":"T36","span":{"begin":71,"end":81},"obj":"Chemical"},{"id":"T37","span":{"begin":181,"end":190},"obj":"Chemical"}],"attributes":[{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A35","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-sentences","denotations":[{"id":"T74","span":{"begin":0,"end":200},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":124,"end":140},"obj":"Phenotype"},{"id":"T11","span":{"begin":157,"end":166},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002721"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Two classes of potential targets are viral polymerases 28 and protease inhibitors 29, both of which are components of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antiviral regimens."}